Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Align Technology I (ALGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 14,303,570
  • Shares Outstanding, K 80,150
  • Annual Sales, $ 1,080 M
  • Annual Income, $ 189,680 K
  • 36-Month Beta 1.55
  • Price/Sales 13.21
  • Price/Cash Flow 64.41
  • Price/Book 13.26

Price Performance

See More
Period Period Low Period High Performance
1-Month
155.55 +8.40%
on 07/27/17
179.76 -6.20%
on 08/16/17
+12.59 (+8.07%)
since 07/18/17
3-Month
136.26 +23.74%
on 05/23/17
179.76 -6.20%
on 08/16/17
+30.92 (+22.46%)
since 05/18/17
52-Week
83.27 +102.49%
on 10/27/16
179.76 -6.20%
on 08/16/17
+73.90 (+78.03%)
since 08/18/16

Most Recent Stories

More News
Zimmer (ZBH) Plagued by Various Internal and External Issues

Zimmer Biomet (ZBH) continues to suffer a bad patch, entangled with issues including its decade-old CEO's recent exit post a dull earnings season due to poor knee business.

ZBH : 111.38 (-0.93%)
LNTH : 15.85 (-1.55%)
IDXX : 150.44 (-0.96%)
ALGN : 168.61 (-0.44%)
Myriad Genetics' EndoPredict Gets Positive Coverage Decision

Considering Myriad Genetics' (MYGN) EndoPredict has been used clinically in more than 15,000 patients, we are confident about the growing adaptability of this test post the Medicare coverage approval.

LNTH : 15.85 (-1.55%)
MYGN : 28.80 (+3.37%)
IDXX : 150.44 (-0.96%)
ALGN : 168.61 (-0.44%)
Walgreens Boots to Gain From Altered Rite Aid Deal, Alliance

The new acquisition deal with Rite Aid would enable Walgreens (WBA) to buy nearly half of its business at a deal value, almost one-third of the original price. Downsides remain a challenge.

RAD : 2.22 (-0.45%)
WBA : 80.03 (-1.06%)
IDXX : 150.44 (-0.96%)
ALGN : 168.61 (-0.44%)
Fluidigm (FLDM) Licenses CFTR Assay From Baylor Genetics

Fluidigm (FLDM) has licensed rights to commercialize the cystic fibrosis transmembrane conductance regulator. The company is focused on improving its Juno automated microfluidic system.

EW : 113.11 (-0.41%)
LNTH : 15.85 (-1.55%)
ALGN : 168.61 (-0.44%)
FLDM : 3.64 (+1.11%)
Allscripts, Elligo Health Enter in Strategic Partnership

Allscripts' (MDRX) Strategic Partnership with Elligo Health would aid the company in capturing the Clinical Research Organizations' lucrative market.

EW : 113.11 (-0.41%)
LNTH : 15.85 (-1.55%)
MDRX : 12.85 (+0.55%)
ALGN : 168.61 (-0.44%)
Walgreens' (WBA) Research Website to Add Value in Healthcare

Walgreens Boots Alliance's (WBA) Center for Health & Wellbeing Research is set to improve patient care and outcomes while reducing health care costs at the same time.

EW : 113.11 (-0.41%)
LNTH : 15.85 (-1.55%)
WBA : 80.03 (-1.06%)
ALGN : 168.61 (-0.44%)
Omnicell Upgrades Web Portal, Grows in Medication Management

Omnicell (OMCL) makes progress in medicare adherence with four new enhancements to its web portal PMAP.

OMCL : 49.55 (+0.51%)
EW : 113.11 (-0.41%)
LNTH : 15.85 (-1.55%)
ALGN : 168.61 (-0.44%)
Henry Schein to Offer CAEK's HIPAA Software LayerCompliance

Henry Schein (HSIC) inks an agreement to distribute CAEK's HIPAA related software, LayerCompliance.

EW : 113.11 (-0.41%)
HSIC : 169.49 (-0.07%)
LNTH : 15.85 (-1.55%)
ALGN : 168.61 (-0.44%)
Here's Why Investors Should Buy Edwards Lifesciences Now

Market is upbeat about Edwards Lifesciences's (EW) recent FDA approvals and strong 2017 guidance.

EW : 113.11 (-0.41%)
LNTH : 15.85 (-1.55%)
IDXX : 150.44 (-0.96%)
ALGN : 168.61 (-0.44%)
Here's Why Investors Should Buy Align Technology (ALGN) Now

Align Technology (ALGN) continues to ride high on robust growth in the Invisalign space.

EW : 113.11 (-0.41%)
LNTH : 15.85 (-1.55%)
STE : 85.13 (-1.28%)
ALGN : 168.61 (-0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Align Technology Inc. designs, manufactures and markets the Invisalign System, a proprietary method for treating malocclusion. The System corrects malocclusion using a series of clear, removable appliances that gently move teeth to a desired final position. Because it does not rely on the use of metal...

See More

Support & Resistance

2nd Resistance Point 174.26
1st Resistance Point 171.44
Last Price 168.61
1st Support Level 166.53
2nd Support Level 164.44

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.